Short Interest in Eyenovia, Inc. (NASDAQ:EYEN) Declines By 41.4%

Eyenovia, Inc. (NASDAQ:EYEN) was the recipient of a large drop in short interest in the month of March. As of March 15th, there was short interest totalling 138,200 shares, a drop of 41.4% from the February 28th total of 236,000 shares. Based on an average trading volume of 447,700 shares, the short-interest ratio is currently 0.3 days. Approximately 6.6% of the shares of the stock are short sold.

Eyenovia Price Performance

NASDAQ EYEN traded down $0.13 on Friday, hitting $1.13. The company had a trading volume of 88,711 shares, compared to its average volume of 151,096. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.74 and a quick ratio of 0.55. The company’s fifty day moving average price is $2.18 and its 200-day moving average price is $16.56. The company has a market capitalization of $1.57 million, a PE ratio of -0.02 and a beta of 1.29. Eyenovia has a 12-month low of $1.13 and a 12-month high of $124.80.

Institutional Trading of Eyenovia

An institutional investor recently raised its position in Eyenovia stock. Geode Capital Management LLC grew its position in Eyenovia, Inc. (NASDAQ:EYEN) by 3.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 577,393 shares of the company’s stock after acquiring an additional 19,399 shares during the quarter. Geode Capital Management LLC owned about 41.54% of Eyenovia worth $84,000 as of its most recent SEC filing. 25.84% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “neutral” rating and set a $2.00 price target on shares of Eyenovia in a research report on Friday, March 21st.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.